Search COVID-19 Rapid Resource Center or explore resources sorted by Category or Content Type.


CDC Resources: Pharmacology

SCCM’s COVID-19 Rapid Resource Center now links to pertinent content from the Centers for Disease Control and Prevention (CDC). These resources are categorized as Pharmacology

The information provided is for educational purposes for SCCM members and the general public. Clicking on these links allows users to leave www.sccm.org. The Society does not control the linked sites or the content on those sites. SCCM does not assume any liability for the content or information contained on these linked sites. Further, SCCM does not assume any liability or warrant with respect to the quality, noninfringement, accuracy, completeness, timeliness, or reliability of such linked sites.You should be aware that other internet sites that link to the Site may contain privacy provisions that differ from these policies. To ensure that your privacy is protected, we recommend that you review the privacy policies of other internet sites you visit.

Vaccine Storage and Handling Toolkit
Best Practices on Vaccine Storage and Handling – An Addendum with best practices and other resources has been added to CDC’s Vaccine Storage and Handling Toolkit to assist COVID-19 vaccination providers with proper storage and handling of COVID-19 vaccines and aims to help providers meet the requirements of the COVID-19 Vaccination Program Provider Agreement. The Addendum will be updated with specific information for each COVID-19 product.

COVID-19 Vaccine Training Module for Healthcare Providers
A new web-on-demand module, COVID-19 Vaccine Training Module for Healthcare Providers, is now available for healthcare providers who will be administering COVID-19 vaccine. The training includes information about COVID-19 vaccine emergency use authorizations, vaccine safety, and general information about vaccine storage, handling, administration, and reporting. 

Frequently Asked Questions about COVID-19 Vaccination
The CDC updates frequently asked questions for Healthcare Infection Prevention and Control and Healthcare Professionals regularly based on feedback from professionals on the ground. 
This information is provided is for educational purposes for SCCM members and the general public. Clicking on these links allows users to leave www.sccm.org. The Society does not control the linked sites or the content on those sites. SCCM does not assume any liability for the content or information contained on these linked sites. Further, SCCM does not assume any liability or warrant with respect to the quality, noninfringement, accuracy, completeness, timeliness, or reliability of such linked sites.You should be aware that other internet sites that link to the Site may contain privacy provisions that differ from these policies. To ensure that your privacy is protected, we recommend that you review the privacy policies of other internet sites you visit.

What Clinicians Need to Know About th Pfizer-BioNTech COVID-19 Vaccine
Information regarding what clinicians need to now about the Pfizer-BioNTech COVID-19 vaccine.

Interim Considerations: Preparing for the Potential Management of Anaphylaxis at COVID-19 Vaccination Sites 
Anaphylaxis is an acute and potentially life-threatening serious allergic reaction. These clinical considerations provide information on preparing for the initial assessment and management of anaphylaxis following COVID-19 vaccination.

Preparing for the Post Vaccine Considerations for Healthcare Personnel
Strategies are needed for healthcare facilities to appropriately evaluate and manage post-vaccination signs and symptoms among healthcare personnel. These considerations are based on the current understanding of signs and symptoms following COVID-19 vaccination, including timing and duration, and might change as experience with the vaccine accumulates.

Different COVID-19 Vaccines 
As COVID-19 vaccines are authorized and then recommended for use in the United States, it will be important to understand what is known about each vaccine. 

Report an Adverse Event to VAERS 
The Vaccine Adverse Event Reporting System (VAERS) is a passive reporting system, meaning it relies on individuals to send in reports of their experiences. Anyone can submit a report to VAERS, including parents and patients.

COVID-19 Podcast - The Latest on the COVID-19 Vaccine 
How safe and efficient are the current COVID-19 vaccine candidates? How are public health systems and health care providers preparing for vaccine administration? Buddy Creech, MD, and Kathryn Edwards, MD, FIDSA, of Vanderbilt University and Dial Hewlett, MD, FIDSA, of the Westchester County Department of Health answer those questions and more.

Moderna COVID-19 Vaccine
This is a link to the CDC COVID-19 external resource regarding interim recommendation for use of Moderna COVID-19 vaccine.

Interim Clinical Considerations for Use of mRNA COVID-19 Vaccines Currently Authorized in the United States
This is a link to the CDC COVID-19 external resource regarding interim clinical considerations for sse of mRNA COVID-19 vaccines currently authorized in the United States.

US COVID-19 Cases Caused by Variants
The cases identified are based on a sampling of SARS-CoV-2-positive specimens and do not represent the total number of B.1.1.7 lineage cases that may be circulating in the United States and may not match numbers reported by states, territories, tribes, and local officials.

Optimizing Personal Protective Equipment (PPE) Supplies
This quick reference summarizes CDC’s strategies to optimize personal protective equipment (PPE) supplies in healthcare settings and provides links to CDC’s full guidance documents on optimizing supplies which provide additional strategies and details.

Summary for Healthcare Facilities: Strategies for Optimizing the Supply of N95 Respirators during Shortages
This summary is intended to help healthcare facilities optimize supplies of disposable N95 filtering facepiece respirators when there is limited supply during the COVID-19 pandemic. 

Frequently Asked Questions about COVID-19 Vaccination in Long-Term Care Facilities
This is a link to the CDC COVID-19 external resource regarding frequently asked questions about COVID-19 vaccination in long-term care facilities.

National Healthcare Safety Network (NHSN) Factsheet: Tracking Healthcare-Associated Infections (HAIs), and Antibiotic Resistance (AR) Infections 
CDC’s National Healthcare Safety Network is supporting the nation’s COVID-19 response by providing a domestic tracking and response system to identify emerging and enduring threats across healthcare, such as COVID-19, healthcare-associated infections (HAIs), and antibiotic-resistant (AR) infections. 

COVID-19 Vaccine FAQs for Healthcare Professionals
This link covers COVID-19 Vaccine FAQs for healthcare professionals.

ACIP Presentation Slides: February 28 - March 1, 2021 Meeting
This is a link to the CDC external resources regarding COVID-19. This link covers the latest ACIP Guidelines regarding the COVID-19 vaccines.

Frequently Asked Questions about v-safe
This is a link to the CDC external resources regarding frequently asked questions about v-safe.

CDC COVID-19 Resource: Johnson & Johnson/Janssen COVID-19 Vaccine and Thrombosis with Thrombocytopenia Syndrome (TTS): Update for Clinicians
The Clinician Outreach and Communication Activity (COCA) held a call Tuesday, April 27, 2021, from 2:00–3:00 p.m. (Eastern Time). During this COCA Call, participants received the latest evidence on thrombosis with thrombocytopenia syndrome (TTS) after administration of the Johnson & Johnson/Janssen COVID-19 vaccine. Speakers discussed information on TTS and updated vaccine recommendations. 

Pediatric Healthcare Professionals COVID-19 Vaccination Toolkit 
The Pediatric Healthcare Professionals COVID-19 Vaccination Toolkit provides materials to help healthcare providers give parents clear and accurate information about COVID-19 vaccines. The toolkit includes answers to common questions, an explanation of how mRNA vaccines work, and printable materials to give to parents. 

COCA Call: What Clinicians Need to Know About Pfizer-BioNTech COVID-19 Vaccination of Adolescents 
The Clinician Outreach and Communication Activity (COCA) held a call Friday, May 14, 2021, from 2:00–3:00 p.m. (Eastern Time). During this COCA call, participants received an overview of the Pfizer-BioNTech COVID-19 vaccination in adolescents who are 12-to-15 years of age. Participants also learned about the safety and efficacy of the vaccine, vaccine recommendations, and clinical guidance for using the Pfizer-BioNTech COVID-19 vaccine in adolescents in this age group. 

Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States
CDC now recommends that people aged 65 years and older, residents in long-term care settings, and people aged 50–64 years with underlying medical conditions should receive a booster shot of Pfizer-BioNTech’s COVID-19 Vaccine at least 6 months after completing their Pfizer-BioNTech primary series. Other groups may receive a booster shot based on their individual risk and benefit. Learn more.
 
Association Between COVID-19 and Myocarditis Using Hospital-Based Administrative Data — United States, March 2020–January 2021
Morbidity and Mortality Weekly Report (MMWR) detailing the association between COVID-19 and Myocarditis.
 
Rapid Increase in Ivermectin Prescriptions and Reports of Severe Illness Associated with Use of Products Containing Ivermectin to Prevent or Treat COVID-19
HAN Archive: Rapid Increase in Ivermectin Prescriptions and Reports of Severe Illness Associated with Use of Products Containing Ivermectin to Prevent or Treat COVID-19

What Clinicians Need to Know about the Recent Updates to CDC’s Recommendations for COVID-19 Boosters (webinar)
This COCA call will provide an overview of the most recent recommendations for administering COVID-19 booster vaccines. The Centers for Disease Control and Prevention will provide updates about the latest recommendations and clinical considerations for administering COVID-19 boosters, including an update on early safety monitoring for additional COVID-19 vaccine doses.
 
CDC Expands Eligibility for COVID-19 Booster Shots
Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States — CDC now recommends that certain people are eligible to receive a COVID-19 booster shot, including those who received Moderna and Johnson & Johnson/Janssen COVID-19 vaccines.

COVID-19 Vaccination for Children 5 through 11 Years Old
Planning for COVID-19 Vaccination for Children 5 – 11 Years Old — The federal government is committed to ensuring children age 5 through 11 have access to COVID-19 vaccines if authorized by the U.S. Food and Drug Administration (FDA) and recommended by CDC’s Advisory Committee on Immunization Practices (ACIP). CDC has developed planning resources for jurisdictions, healthcare providers, pharmacists and community partners.
 
Pediatric COVID-19 Vaccines: CDC’s Recommendations for Pfizer-BioNTech COVID-19 Vaccine Primary Series in Children 5–11 Years Old
COCA Call: Pediatric COVID-19 Vaccines: CDC’s Recommendations for Pfizer-BioNTech COVID-19 Vaccine Primary Series in Children 5–11 Years Old — During this COCA call, CDC provided an overview of its recommendations and clinical considerations for administering the Pfizer-BioNTech COVID-19 vaccination primary series in children aged 5–11 years old.
 


Estimated Time:

Categories: Disaster, Immunology, Pharmacology, Procedures,
Content Type: External Resource,